PriceTargets.com logo

NASDAQ:APTX - Aptinyx Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $10.50
  • Forecasted Upside: 333.88 %
  • Number of Analysts: 7
  • Breakdown:
  • 1 Sell Ratings
  • 0 Hold Ratings
  • 6 Buy Ratings
  • 0 Strong Buy Ratings
$2.42 As of 09/16/2021 04:08 PM ET
▲ +0.02 (0.83%)

This chart shows the closing price for APTX by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Aptinyx Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for APTX and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for APTX

Analyst Price Target is $10.50
▲ +333.88% Upside Potential
This price target is based on 7 analysts offering 12 month price targets for Aptinyx in the last 3 months. The average price target is $10.50, with a high forecast of $12.00 and a low forecast of $8.00. The average price target represents a 333.88% upside from the last price of $2.42.

This chart shows the closing price for APTX for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 7 polled investment analysts is to buy stock in Aptinyx. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 1 sell ratings
Ratings as of
3/24/2020
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 1 sell ratings
Ratings as of
6/22/2020
  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
9/20/2020
  • 0 strong buy ratings
  • 8 buy ratings
  • 0 hold ratings
  • 1 sell ratings
Ratings as of
12/19/2020
  • 0 strong buy ratings
  • 8 buy ratings
  • 0 hold ratings
  • 1 sell ratings
Ratings as of
3/19/2021
  • 0 strong buy ratings
  • 8 buy ratings
  • 0 hold ratings
  • 1 sell ratings
Ratings as of
6/17/2021
  • 0 strong buy ratings
  • 6 buy ratings
  • 0 hold ratings
  • 1 sell ratings
Ratings as of
8/16/2021
  • 0 strong buy ratings
  • 6 buy ratings
  • 0 hold ratings
  • 1 sell ratings
Ratings as of
9/15/2021

Latest Recommendations

  • 0 strong buy ratings
  • 6 buy ratings
  • 0 hold ratings
  • 1 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
4/9/2021HC WainwrightReiterated RatingBuy$8.00High
1/29/2021JPMorgan Chase & Co.DowngradeNeutral ➝ UnderweightMedium
11/19/2020HC WainwrightBoost Price TargetPositive ➝ Buy$7.00 ➝ $8.00High
11/13/2020SVB LeerinkLower Price TargetOutperform$14.00 ➝ $12.00High
10/28/2020Cantor FitzgeraldBoost Price TargetOverweight$9.00 ➝ $12.00High
10/27/2020Piper SandlerInitiated CoverageOverweight$10.00Low
10/21/2020CowenReiterated RatingBuyMedium
10/20/2020SVB LeerinkBoost Price TargetOutperform$12.00 ➝ $14.00Low
10/14/2020JPMorgan Chase & Co.Initiated CoverageNeutralMedium
10/1/2020William BlairReiterated RatingBuyLow
8/14/2020BMO Capital MarketsReiterated RatingBuy$13.00Medium
7/1/2020SunTrust BanksInitiated CoverageBuy$15.00High
6/18/2020HC WainwrightReiterated RatingBuy$7.00High
5/7/2020William BlairInitiated CoverageOutperformMedium
4/29/2020HC WainwrightInitiated CoverageBuy$7.00High
11/14/2019CowenReiterated RatingBuyHigh
9/12/2019WedbushInitiated CoverageOutperform$7.00High
8/13/2019JPMorgan Chase & Co.DowngradeNeutral ➝ UnderweightHigh
6/20/2019SVB LeerinkInitiated CoverageOutperform ➝ Outperform$12.00High
6/10/2019CowenReiterated RatingBuyHigh
4/30/2019Cantor FitzgeraldReiterated RatingBuyLow
3/22/2019BMO Capital MarketsReiterated RatingOutperformHigh
3/22/2019Cantor FitzgeraldLower Price TargetOverweight ➝ Overweight$18.00 ➝ $12.00High
1/18/2019BMO Capital MarketsLower Price TargetOutperform$18.00Low
1/17/2019SVB LeerinkLower Price TargetOutperform$35.00 ➝ $22.00High
1/17/2019JPMorgan Chase & Co.DowngradeOverweight ➝ Neutral$30.00 ➝ $8.00High
1/16/2019Cantor FitzgeraldReiterated RatingBuy$40.00High
12/3/2018Cantor FitzgeraldReiterated RatingBuy$40.00Low
11/14/2018Cantor FitzgeraldInitiated CoverageOverweight ➝ Overweight$40.00High
7/16/2018SVB LeerinkInitiated CoverageOutperform$35.00Low
7/16/2018CowenInitiated CoverageOutperformHigh
7/16/2018JPMorgan Chase & Co.Initiated CoverageOverweight$30.00Low
7/16/2018BMO Capital MarketsInitiated CoverageOutperform$32.00Low
(Data available from 9/16/2016 forward)

News Sentiment Rating

0.23 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 2 very positive mentions
  • 4 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
2/18/2021
  • 0 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
3/20/2021
  • 0 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
4/19/2021
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
5/19/2021
  • 0 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
6/18/2021
  • 0 very positive mentions
  • 3 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
7/18/2021
  • 0 very positive mentions
  • 6 positive mentions
  • 4 negative mentions
  • 1 very negative mentions
Mentions as of
8/17/2021
  • 0 very positive mentions
  • 6 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
9/16/2021

Current Sentiment

  • 0 very positive mentions
  • 6 positive mentions
  • 1 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

Positive

Very Positive

Aptinyx logo
Aptinyx Inc. is a clinical stage biopharmaceutical company. It engages in the discovery, development, and commercialization of transformative therapies for disorders of the brain and nervous system. Its product includes NYX-2925, NYX-783, NYX-458, and the AGN-241751 program. The company was founded by Norbert G. Riedel and Joseph R. Moskal in June 2015 and is headquartered in Evanston, IL.
Read More

Today's Range

Now: $2.42
Low: $2.35
High: $2.42

50 Day Range

MA: $2.56
Low: $2.21
High: $2.89

52 Week Range

Now: $2.42
Low: $2.16
High: $6.47

Volume

1,744 shs

Average Volume

688,872 shs

Market Capitalization

$163.87 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.37

Frequently Asked Questions

What sell-side analysts currently cover shares of Aptinyx?

The following sell-side analysts have issued research reports on Aptinyx in the last year: Cantor Fitzgerald, Cowen Inc, HC Wainwright, JPMorgan Chase & Co., Piper Sandler, SVB Leerink LLC, William Blair, and Zacks Investment Research.
View the latest analyst ratings for APTX.

What is the current price target for Aptinyx?

4 Wall Street analysts have set twelve-month price targets for Aptinyx in the last year. Their average twelve-month price target is $10.50, suggesting a possible upside of 346.8%. Cantor Fitzgerald has the highest price target set, predicting APTX will reach $12.00 in the next twelve months. HC Wainwright has the lowest price target set, forecasting a price of $8.00 for Aptinyx in the next year.
View the latest price targets for APTX.

What is the current consensus analyst rating for Aptinyx?

Aptinyx currently has 1 sell rating and 6 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe APTX will outperform the market and that investors should add to their positions of Aptinyx.
View the latest ratings for APTX.

What other companies compete with Aptinyx?

Other companies that are similar to Aptinyx include Endo International, Pharming Group, Eliem Therapeutics, Summit Therapeutics, Rhythm Pharmaceuticals, Landos Biopharma, Vera Therapeutics, DiaMedica Therapeutics, Affimed, Seres Therapeutics, Spero Therapeutics, G1 Therapeutics, Calliditas Therapeutics AB (publ), Bolt Biotherapeutics and NRx Pharmaceuticals.

How do I contact Aptinyx's investor relations team?

Aptinyx's physical mailing address is 909 DAVIS STREET SUITE 600, EVANSTON IL, 60201. The company's listed phone number is (847) 871-0377 and its investor relations email address is [email protected] The official website for Aptinyx is www.aptinyx.com.